Treatment of Dermatophytosis (Ringworm) with Unani medicine Majoon-e-Ushba and Marham Qooba

Phase 3

Not yet recruiting

Conditions: Dermatophytosis, unspecified,

Registration Number: CTRI/2019/02/017857

Lead Sponsor: Central Council for Research in Unani Medicine CCRUM

Brief Summary: This study is designed as a multicentric open trial in patients with **Qooba (Dermatophytosis)****.**After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria. The patients will be assessed clinically at week 0, 02 and 05. This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 5 weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of** ***Majoon-e-Ushba***

| | | | |

| --- | --- | --- | --- |

|**S. No.**

**Unani Name**

**Scientific Name**

**Weight**

|1.

Ushba

*Smilax ornate* Lem.

20 g

|2.

Bisfaij Fastaqi

*Polypodium vulgare* Linn.

20 g

|3.

Aftimun Vilayti

*Cuscuta eurea* Linn.

20 g

|4.

Barg-e-Gawzaban

*Onasma bracteatum* Wall.

20 g

|5.

Kabab chini

*Piper cuceba* Linn.

20 g

|6.

Darchini

*Cinnamonium zeylanicum*

20 g

|7.

Gule Surkh

*Rosa damascene*

30 g

|8.

Chobchini

*Smilax china* Linn.

30 g

|9.

Sandal Safaid

*Santalum album* Linn.

30 g

|10.

Sandal Surkh

*Pterocarpus santalinus* Linn.

30 g

|11.

Senna Makki

*Cassia angustifolia*

40 g

|12.

Post Balela,

*Terminalia belirica* Roxb.

10 g

|13.

Sumbul-ut-Teeb

*Valeriana jatamansi* DC.

10 g

|14.

Halela Siyah

*Terminalia chebula* Retz.(Black)

7 g

|15.

Post Halela Zard

*Terminalia chebula* Retz.(yellow)

6 g

|16.

Qand Safaid

Sucrose

750 g

|17.

Shahad

Honey

500 g

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 240

Inclusion Criteria

Patients of either sex aged between 18- 65 years 2.
Subjects with KOH positive/microscopically confirmed 3.
Clinical signs and symptoms suggestive of fungal infection viz.
annular / arcuate polycyclic lesion with clear centre and an active margin with papulo-vesicles & scaling; erythema, itching, burning.

Exclusion Criteria

Patients of either sex < 18 years and > 65 years 2.
Superficial skin disease like Eczema/psoriasis/scabies 3.
Superadded infections 4.
Lactating and pregnant women 5.
Subjects with Tinea capitis (tinea of scalp), Onychomycosis (tinea of nails) and Tinea barbae (tinea of beard) 6.
Subjects who are concomitantly using any anti-fungal product in any form 7.
Known cases of allergy to any ingredients of the study drug 8.
Subjects with systemic diseases requiring long-term treatment 9.
Subjects not willing to undergo the specified washout periods (for topical preparations not less than 2 weeks & for systemic medicines 4 weeks).

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in sign and symptoms of Qooba (Dermatophytosis)	05 weeks.

Secondary Outcome Measures

Name	Time	Method
Haematological and biochemical assessment for safety assessment	Investigations will be done at baseline and end of treatment

Trial Locations

Locations (1): Regional Research Institute of Unani Medicine (RRIUM)
🇮🇳
Patna, BIHAR, India
Regional Research Institute of Unani Medicine (RRIUM)
🇮🇳Patna, BIHAR, India
Dr Irfan Ahmad
Principal investigator
02223742173
rrium.mumbai@gmail.com
Dr K Kabiruddin Ahmed
Principal investigator
9444219145
drk.kabiruddin@rediffmail.com
Dr Mohd Manzar Alam
Principal investigator
7488966960
manzar.medicine@gmail.com